Cholestyramine — Discount Pricing
Cholestyramine is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Cholestyramine Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $199.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Cholestyramine
Cholestyramine is a prescription medication. Ask your doctor if Cholestyramine is right for you.
How to Check Cholestyramine Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Cholestyramine at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Heart & Cardiovascular
What Cholestyramine is approved for (FDA label)
1) Cholestyramine for oral suspension, USP powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low-density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for oral suspension, USP powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy.
Source: Read the full FDA label on DailyMed. Label effective date: August 20, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Cholestyramine (FDA label)
The most common adverse reaction is constipation. When used as a cholesterol-lowering agent predisposing factors for most complaints of constipation are high dose and increased age (more than 60 years old). Most instances of constipation are mild, transient and controlled with conventional therapy. Some patients require a temporary decrease in dosage or discontinuation of therapy. Less Frequent Adverse Reactions: Abdominal discomfort and/or pain, flatulence, nausea, vomiting, diarrhea, eructation, anorexia, steatorrhea, bleeding tendencies due to hypoprothrombinemia (Vitamin K deficiency) as well as Vitamin A (one case of night blindness reported) and D deficiencies, hyperchloremic acidosis in children, osteoporosis, rash and irritation of the skin, tongue and perianal area.
Source: FDA prescribing information (DailyMed). Set ID: 214ea05f-de81-4026-9df9-4ce3820668ee. SPL document ID: 6c8521c7-d18f-4416-bcd3-9f55e17ec90b. Label effective date: August 20, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Cholestyramine (FDA label)
Cholestyramine for oral suspension, USP powder is contraindicated in patients with complete biliary obstruction where bile is not secreted into the intestine and in those individuals who have shown hypersensitivity to any of its components.
Source: FDA prescribing information (DailyMed). Set ID: 214ea05f-de81-4026-9df9-4ce3820668ee. SPL document ID: 6c8521c7-d18f-4416-bcd3-9f55e17ec90b. Label effective date: August 20, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Cholestyramine (FDA label)
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins and digitalis. Interference with the absorption of oral phosphate supplements has been observed with another positively charged bile acid sequestrant. Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation. The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been titrated to a maintenance level while the patient was taking cholestyramine resin.
Source: FDA prescribing information (DailyMed). Set ID: 214ea05f-de81-4026-9df9-4ce3820668ee. SPL document ID: 6c8521c7-d18f-4416-bcd3-9f55e17ec90b. Label effective date: August 20, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.